search
Back to results

Lower Limb Blood Flow Geko vs Foot Pump

Primary Purpose

Venous Thrombosis, Arthroplasty, Replacement, Hip

Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Neuromuscular electrostimulation (NMES) device
Intermittent pneumatic compression (IPC) device
Sponsored by
Hampshire Hospitals NHS Foundation Trust
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Venous Thrombosis focused on measuring venous thromboembolism, deep vein thrombosis, pulmonary embolism, neuromuscular electrostimulation, foot compression, hip replacement

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • patients undergoing primary THA,
  • in good general health and fitness,
  • age 18 years or over
  • able to provide written informed consent.

Exclusion Criteria:

  • Are requiring hip revision surgery
  • Previous or current diagnosis of deep vein thrombosis (DVT) or pulmonary embolism (PE).
  • History or signs of significant haematological disorders (especially in relation to clotting or coagulation) or thrombophlebitis.
  • Peripheral arterial disease, clinically significant varicose veins or lower limb ulceration or ischemia.
  • Recent surgery within the last 3 months (such as abdominal, gynaecological, hip or knee replacement).
  • Recent trauma to lower limb.
  • Chronic Obesity (BMI Index >40kg/m2).
  • Pregnancy.
  • Significant history of following diseases i. Cardiovascular: Recent MI (< 6 months) ii. Percutaneous Coronary Intervention (PCI) with stent (< 3 months for Bare metal stent (BMS) and < 12 months for Drug Eluding Stent (DES) iii. Moderate to severe CCF, uncontrolled AF iv. Neurological: Stroke, Hemiplegia/Paraplegia, Myopathies v. Renal: Moderate to severely impaired renal function vi. Hepatic: Moderate to severely impaired hepatic function vii. Psychiatric disorders viii. Dermatological conditions affecting lower limbs
  • On LMWH/Heparin (Prophylactic/therapeutic doses) or Warfarin or warfarin stopped recently and replaced by LMWH/ Heparin
  • Long term steroid use with dermatological changes
  • A pulse rate of less than 40 beats/minute
  • A sitting systolic blood pressure >180 and <100 mmHg and/or a sitting diastolic pressure of >100 mmHg.
  • Participation in any clinical study during the eight (8) weeks preceding the screening period
  • THR done for hip fracture

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Active Comparator

    Arm Label

    Arm A (NMES followed by IPC)

    Arm B (IPC followed by NMES)

    Arm Description

    Arm A (NMES followed by IPC). Following baseline blood flow measurements using ultrasound, the neuromuscular electrostimulation (NMES) device will be fitted and allowed to operate for 10 minutes. Blood flow measurements will then be repeated. The NMES device will be removed. After a 30 minute rest period, the intermittent pneumatic compression (IPC) device will be fitted, activated for 10 minutes and then blood flow measurements repeated.

    Arm B (IPC followed by NMES). Following baseline blood flow measurements using ultrasound, the intermittent pneumatic compression device (IPC) will be fitted and allowed to operate for 10 minutes. Blood flow measurements will then be repeated. The IPC device will be removed. After a 30 minute rest period, the neuromuscular electrostimulation (NMES) device will then be fitted, activated for 10 minutes and then blood flow measurements repeated

    Outcomes

    Primary Outcome Measures

    Venous flow at baseline
    Measured within the superficial femoral vein using ultrasound
    Venous flow after application of device 1
    Measured within the superficial femoral vein using ultrasound
    Venous flow after application of device 2
    Measured within the superficial femoral vein using ultrasound

    Secondary Outcome Measures

    Patient satisfaction with device 1
    verbal rating score: 1 extremely comfortable, 2 comfortable, 3 uncomfortable, 4 very uncomfortable, 5 extremely uncomfortable.
    Patient satisfaction with device 2
    verbal rating score: 1 extremely comfortable, 2 comfortable, 3 uncomfortable, 4 very uncomfortable, 5 extremely uncomfortable.

    Full Information

    First Posted
    October 12, 2017
    Last Updated
    September 20, 2021
    Sponsor
    Hampshire Hospitals NHS Foundation Trust
    Collaborators
    Firstkind Ltd
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03317145
    Brief Title
    Lower Limb Blood Flow Geko vs Foot Pump
    Official Title
    Intermittent Pneumatic Compression (IPC) of the Foot Versus Geko™ Neuromuscular Electrostimulation (NMES): Comparison of Lower Limb Circulation Following Elective Total Hip Replacement (THR)
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    October 2017
    Overall Recruitment Status
    Completed
    Study Start Date
    July 24, 2013 (Actual)
    Primary Completion Date
    February 19, 2014 (Actual)
    Study Completion Date
    February 19, 2014 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Hampshire Hospitals NHS Foundation Trust
    Collaborators
    Firstkind Ltd

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Product Manufactured in and Exported from the U.S.
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The aim of this pilot study was to assess venous flow parameters in patients following total hip arthroplasty, comparing an intermittent pneumatic compression foot device with a portable neuromuscular electrostimulator device. Assessments were performed in a single sitting before hospital discharge, between days 1 to 4 post operatively. The total duration of participation for each patient who completed the study was approximately 2.5 hours.
    Detailed Description
    Ethical approval was obtained from the National Research Ethics Service (Edgbaston), reference 13/WM/0139. Upon admission to hospital for THA, eligible patients were invited to participate in the study. Inclusion criteria were: patients undergoing primary THA, in good general health and fitness, age 18 years or over and the ability to provide written informed consent. Patients were taken to the ultrasound suite within the first three days following surgery. Baseline ultrasound Patients lay in bed, the back supported at approximately 45 degrees, legs lying horizontal with their knees extended. Duplex ultrasound was then performed on the superficial femoral vein (Acuson S2000, Siemens). Baseline bilateral venous assessments of peak velocity, mean velocity, volume flow and vessel diameter were taken in triplicate. All scans were performed by the same ultrasonographer for consistency. Gate size was adjusted to just within the vessel wall. Randomisation Following baseline measurements, patients were fitted with either the NMES device or an IPC device, the order determined by randomisation using online software. A representative from the study sponsor provided sealed envelopes containing the arm to be randomised which was opened on the day of testing. Patients were randomised into arm A (NMES first, IPC second) or arm B (IPC first, NMES second). Blinding was not possible because the obvious physical differences between the two devices. Following testing of the first device, a 30-minute rest period was then given. The second device was then tested. All devices were fitted by the first author. All patients underwent scanning by the same sonographer to ensure consistency in data recording. NMES application The NMES device (Geko T-1, Firstkind Ltd., High Wycombe, United Kingdom) was applied to both legs as per the manufacturer's instructions. The skin over the fibula head was prepared with an exfoliation pad, followed by an alcohol wipe. The device was applied to the skin using an adhesive strip and positioned so that the built-in electrodes were positioned over the common peroneal nerve. An overlay strip was then used to improve skin contact. A charge balanced short single pulse with a current of 27mA was delivered at a frequency of once per second. The pulse width adjustment has seven selectable stimulation settings ranging from 70 - 560 μs and was increased until a visible foot twitch was produced. Following successful application of the device for ten minutes, venous blood flow measurements were repeated. IPC application An IPC device (Vadoplex, OPED UK, UK) was fitted to each foot as per the manufacturer's instructions and activated for ten minutes prior to recording venous flow. The IPC provides a pump inflation pressure of 120mmHg, inflating once every 20 seconds. Each inflation was maintained for approximately 1 second, before deflation occurred. The maximum recording duration of the ultrasound scanner was 14 seconds. In order to capture 20 seconds of data, two contiguous measurements of 14 and 6 seconds were made. The machine records flow within the vessel. Since flow varies within the vessel, the machine is able to use a complex algorithm to sample velocities and flow over time and hence calculate the mean. In order to calculate mean velocity and volume flow over a complete 20 second cycle, we used the following equation: Measure the blood flow during inflation (F1) and record the time duration of this flow (A). Measure the blood flow during the opposite, deflated, part of the cycle (F2) and record the total cycle duration (B). The calculation below provides a summated value for flow. Total flow = [(A/B) x F1)] + [(1-(A/B)) x F2] Device acceptability Patients were asked to rate comfort of the devices using a verbal rating score: 1 extremely comfortable, 2 comfortable, 3 uncomfortable, 4 very uncomfortable, 5 extremely uncomfortable. Power analysis and statistical analysis Data from an unpublished study in healthy volunteers of the NMES device verses IPC comparing venous flow parameters, showed a significant benefit of NMES, with an effect size of 1.4 (Cohen's d). Sample size calculation based on this effect size gave a power in excess of 90% for a design of ten subjects per site. We checked for significant association (p<0.05) of device, measurement order and leg on blood flow parameters of interest using generalized linear latent and mixed model with a random effects term to account for repeated measures on a given subject using Stata10 (Stata Corp, college station, TX). Blood flow parameters are reported as mean and 95% confidence intervals (CI). A Wilcoxon signed rank test was used to analyse the verbal rating scores for patient comfort.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Venous Thrombosis, Arthroplasty, Replacement, Hip
    Keywords
    venous thromboembolism, deep vein thrombosis, pulmonary embolism, neuromuscular electrostimulation, foot compression, hip replacement

    7. Study Design

    Primary Purpose
    Prevention
    Study Phase
    Not Applicable
    Interventional Study Model
    Sequential Assignment
    Model Description
    Patients who have had a total hip replacement will be randomised to wear either a foot compression (IPC) device or a neuromuscular electrostimulation (NMES) device (gekoTM) first. Blood flow will be measured using both devices on the same patient in sequence. The blood flow measurements will be done by ultrasound. Each ultrasound assessment will take approximately 30 minutes in total. Baseline blood flow measurements will be taken initially. The first device will then be fitted and allowed to operate for 10 minutes before ultrasound measurements are taken. After a rest period of 30 minutes, the second device is then fitted and allowed to operate for 10 minutes, following which blood flow measurements are repeated. Patients will then be asked to complete a questionnaire to assess the comfort of each device.
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    10 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Arm A (NMES followed by IPC)
    Arm Type
    Active Comparator
    Arm Description
    Arm A (NMES followed by IPC). Following baseline blood flow measurements using ultrasound, the neuromuscular electrostimulation (NMES) device will be fitted and allowed to operate for 10 minutes. Blood flow measurements will then be repeated. The NMES device will be removed. After a 30 minute rest period, the intermittent pneumatic compression (IPC) device will be fitted, activated for 10 minutes and then blood flow measurements repeated.
    Arm Title
    Arm B (IPC followed by NMES)
    Arm Type
    Active Comparator
    Arm Description
    Arm B (IPC followed by NMES). Following baseline blood flow measurements using ultrasound, the intermittent pneumatic compression device (IPC) will be fitted and allowed to operate for 10 minutes. Blood flow measurements will then be repeated. The IPC device will be removed. After a 30 minute rest period, the neuromuscular electrostimulation (NMES) device will then be fitted, activated for 10 minutes and then blood flow measurements repeated
    Intervention Type
    Device
    Intervention Name(s)
    Neuromuscular electrostimulation (NMES) device
    Other Intervention Name(s)
    Geko T-1
    Intervention Description
    A mobile peroneal nerve stimulator
    Intervention Type
    Device
    Intervention Name(s)
    Intermittent pneumatic compression (IPC) device
    Other Intervention Name(s)
    Vadoplex
    Intervention Description
    A foot pump or foot compression device
    Primary Outcome Measure Information:
    Title
    Venous flow at baseline
    Description
    Measured within the superficial femoral vein using ultrasound
    Time Frame
    "t0" - 30 minutes to include the ultrasound assessment, performed between days 1 and 4 post operatively
    Title
    Venous flow after application of device 1
    Description
    Measured within the superficial femoral vein using ultrasound
    Time Frame
    "t1" - 90 minutes to include the ultrasound assessment
    Title
    Venous flow after application of device 2
    Description
    Measured within the superficial femoral vein using ultrasound
    Time Frame
    "t2" - 150 minutes to include the ultrasound assessment
    Secondary Outcome Measure Information:
    Title
    Patient satisfaction with device 1
    Description
    verbal rating score: 1 extremely comfortable, 2 comfortable, 3 uncomfortable, 4 very uncomfortable, 5 extremely uncomfortable.
    Time Frame
    Immediately after completion of the ultrasound assessment for device 1, at "t1" - 90 minutes
    Title
    Patient satisfaction with device 2
    Description
    verbal rating score: 1 extremely comfortable, 2 comfortable, 3 uncomfortable, 4 very uncomfortable, 5 extremely uncomfortable.
    Time Frame
    Immediately after completion of the ultrasound assessment for device 2, at "t2" - 150 minutes

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: patients undergoing primary THA, in good general health and fitness, age 18 years or over able to provide written informed consent. Exclusion Criteria: Are requiring hip revision surgery Previous or current diagnosis of deep vein thrombosis (DVT) or pulmonary embolism (PE). History or signs of significant haematological disorders (especially in relation to clotting or coagulation) or thrombophlebitis. Peripheral arterial disease, clinically significant varicose veins or lower limb ulceration or ischemia. Recent surgery within the last 3 months (such as abdominal, gynaecological, hip or knee replacement). Recent trauma to lower limb. Chronic Obesity (BMI Index >40kg/m2). Pregnancy. Significant history of following diseases i. Cardiovascular: Recent MI (< 6 months) ii. Percutaneous Coronary Intervention (PCI) with stent (< 3 months for Bare metal stent (BMS) and < 12 months for Drug Eluding Stent (DES) iii. Moderate to severe CCF, uncontrolled AF iv. Neurological: Stroke, Hemiplegia/Paraplegia, Myopathies v. Renal: Moderate to severely impaired renal function vi. Hepatic: Moderate to severely impaired hepatic function vii. Psychiatric disorders viii. Dermatological conditions affecting lower limbs On LMWH/Heparin (Prophylactic/therapeutic doses) or Warfarin or warfarin stopped recently and replaced by LMWH/ Heparin Long term steroid use with dermatological changes A pulse rate of less than 40 beats/minute A sitting systolic blood pressure >180 and <100 mmHg and/or a sitting diastolic pressure of >100 mmHg. Participation in any clinical study during the eight (8) weeks preceding the screening period THR done for hip fracture
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Geoff Stranks, FRCS
    Organizational Affiliation
    North Hampshire Hospital, Basingstoke
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No
    IPD Sharing Plan Description
    We would be happy to share individual participant data if requested by other researchers although have no formal plans to publish this at present. All data shared would be anonymised.
    Citations:
    PubMed Identifier
    23999610
    Citation
    Warwick DJ, Shaikh A, Gadola S, Stokes M, Worsley P, Bain D, Tucker AT, Gadola SD. Neuromuscular electrostimulation viathe common peroneal nerve promotes lower limb blood flow in a below-kneecast: A potential for thromboprophylaxis. Bone Joint Res. 2013 Sep 2;2(9):179-85. doi: 10.1302/2046-3758.29.2000176. Print 2013.
    Results Reference
    background
    PubMed Identifier
    24722790
    Citation
    Williams KJ, Moore HM, Davies AH. Haemodynamic changes with the use of neuromuscular electrical stimulation compared to intermittent pneumatic compression. Phlebology. 2015 Jun;30(5):365-72. doi: 10.1177/0268355514531255. Epub 2014 Apr 10.
    Results Reference
    background

    Learn more about this trial

    Lower Limb Blood Flow Geko vs Foot Pump

    We'll reach out to this number within 24 hrs